Nautilus Biotechnology Inc (NAS:NAUT)
$ 2.255 0.015 (0.67%) Market Cap: 282.47 Mil Enterprise Value: 130.34 Mil PE Ratio: 0 PB Ratio: 1.13 GF Score: 38/100

Nautilus Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 03:05PM GMT
Release Date Price: $2.37 (+4.41%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, guys. So we're just going to get started here. My name is Tejas Savant. I'm the life science tools and diagnostics analyst here at Morgan Stanley. It's my pleasure to host Sujal Patel from Nautilus and Anna Mowry who's sitting in the audience here, who's the CFO of the company. Before we get started, I just wanted to read the standard disclaimer here. For important disclosures, please see the research website at morganstanley.com/researchdisclosures. And if you have any questions, please do reach out to your sales rep. So with that, Sujal, thank you for doing this.

Questions & Answers

Tejas Rajeev Savant;Sujal M. Patel
Morgan Stanley, Research Division - Equity Analyst;Nautilus Biotechnology,

Maybe to start for people in the audience perhaps who are not as familiar with Nautilus, can you just provide a brief history of the company, how it came into being? And what are the key unmet needs in the proteomics market that you are trying to address?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot